The dawn of “personalised” cancer therapy

Exciting advancements in mRNA therapeutics over recent years have led to the recent launch of a phase 3 clinical trial for the world's first "personalised" mRNA vaccine to treat melanoma.

20 years and 1000 cases

We bring a rich history working with pioneers of their time on mission-critical, life-changing and industry-advancing innovations. For Panduit, a world-leading network infrastructure developer, we’re more than an extension of their in-house team. We’re family.

See why clients choose us

Client quote:

'I have often said that no one will out think, out prepare or out perform you. I am glad you are on our side!'

Our services have helped our clients’ innovations make a real difference; from the steel of the Golden Gate Bridge to cutting-edge cancer fighting pharmaceuticals.

Accolades

News & Updates

EPO Board of Appeal clarifies the bar for AI/ML patent disclosure: T 1669/21 case note

The EPO Board of Appeal recently handed down a decision in case T 1669/21 that has important implications for patent practitioners drafting machine learning patent applications.

Parameters at the EPO: Tips and common pitfalls

Many inventions, particularly in the chemical field, are defined by ‘parameters’ rather than structural features. Parameters are measurable physical or chemical properties used to define an invention where using structural features would not be possible or would be too limiting.

Nobel Prize awarded for the discovery of microRNA and its role in post-transcriptional gene regulation

Congratulations to Victor Ambros and Gary Ruvkun who were jointly awarded the 2024 Nobel Prize in Physiology or Medicine for their discovery of microRNA in the small worm C. elegans.

Upcoming events

19 November 2024 - Attacking MedTech patents in the US and Europe – strategies for post-grant proceedings at the USPTO, the EPO and the UPC

Join us for this 30-minute webinar where experts from Kilburn & Strode and Meunier, Curlin & Curfman will explore the key strategies for challenging MedTech patents in the United States and Europe.

Celebrating diversity: IP Inclusive

Fiercely committed to diversity, equity and inclusion, we were one of the first signatories of the IP Inclusive Charter, making a public commitment to supporting and promoting DEI in the IP professions. Additionally, we were founding members of IP Out, our LGBT+ chapter, and we regularly host events for Senior Women in IP and on neurodiversity, sustainability, and more.

Technology for Good

We care about the wider innovation and technology community, which is why we donate 1% of all annual profits to the Kilburn & Strode Innovation for All Foundation – thereby giving everyone the chance to both innovate and prosper. Our company’s existence is not isolated. It’s part of a wider system of people, values, other organisations and nature.

Let us keep you up to date. If you’d like to receive communications from us, ranging from breaking news to technical updates, thought leadership to event invitations, please let us know.

Connect with us